GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

March 27 () - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful reduction in ...

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.

AstraZeneca (AZN) announced on Friday that its antibody therapy, tozorakimab, reached the key goals in two Phase 3 trials for patients with chronic obstructive pulmonary disease, a respiratory disease ...

Oxygen therapy can help people with COPD breathe better and do daily activities with less difficulty. There are three types of oxygen therapy: compressed oxygen cylinders, liquid oxygen, and oxygen ...

Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

Effective treatment often requires you to take medications to better manage symptoms or stop taking medications if a doctor advises that you no longer need them. Finding the right dosages and ...

By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...